In vitro cytotoxicity of 2-chlorodeoxyadenosine and chlorambucil in chronic lymphocytic leukemia

Leukemia

Volumn 10, Issue 12, 1996, Pages 1959-1965

  Begleiter, A ^a,b   Wang, H ^b   Verburg, L ^a   Lee, K ^a   Israels, L G ^a,b   Mowat, M R A ^a,b   Johnston, J B ^a,b  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

Author keywords

2 chlorodeoxyadenosine; Chlorambucil; Chronic lymphocytic leukemia; Combination therapy

Indexed keywords

CHLORAMBUCIL; CLADRIBINE;

ADULT; AGED; ARTICLE; BONE MARROW; CHEMOSENSITIVITY; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DNA CROSS LINKING; DNA REPAIR; DRUG CYTOTOXICITY; DRUG DNA INTERACTION; ERYTHROID PRECURSOR CELL; FEMALE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL;

EID: 0030451076     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. O'Brien S, del Giglio A, Keating M. Advances in the biology and treatment of B-cell chronic lymphocytic leukemia. Blood 1995; 85: 307-318.
2. Begleiter A, Lee K, Israels LG, Mowat MRA, Johnston JB. Chlorambucil induced apoptosis in chronic lymphocytic leukemia (CLL) and its relationship to clinical efficacy. Leukemia 1994; 8 (Suppl. 1): S103-S106.
3. Bank BB, Kanganis D, Liebes LF, Silber R. Chlorambucil pharmacokinetics and DNA binding in chronic lymphocytic leukemia lymphocytes. Cancer Res 1989; 49: 554-559.
4. Begleiter A, Goldenberg GJ, Anhalt CD, Lee K, Mowat MR, Israels LG, Johnston JB. Mechanisms of resistance to chlorambucil in chronic lymphocytic leukemia. Leuk Res 1991; 15: 1019-1027.
5. Juliusson G, Liliemark J. High complete remission rate from 2-chloro-2′-deoxyadenosine in previously treated patients with B-cell chronic lymphocytic leukemia: response predicted by rapid decrease of blood lymphocyte count. J Clin Oncol 1993; 11: 679-689.
6. Tallman MS, Hakimian D, Zanzig C, Hogan DK, Rademaker A, Rose E, Variakojis D. Cladribine in the treatment of relapsed or refractory chronic lymphocytic leukemia. J Clin Oncol 1995; 13: 983-988.
7. Saven A, Lemon RH, Kosty M, Beutler E, Piro LD. 2-Chlorodeoxyadenosine activity in patients with untreated chronic lymphocytic leukemia. J Clin Oncol 1995; 13: 570-574.
8. O'Brien S, Kantarjian H, Beran M, Smith T, Koller C, Estey E, Robertson LE, Lerner S, Keating M. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia and multivariate analysis-derived prognostic model for response to treatment. Blood 1993; 82: 1695-1700.
9. Keating MJ, O'Brien S, Plunkett W, Robertson LE, Gandhi V, Estey E, Dimopoulos M, Cabanillas F, Kemena A, Kantarjian H. Fludarabine phosphate: a new active agent in hematologic malignancies. Semin Hematol 1994; 31: 28-39.
10. Dillman RO, Mick R, McIntyre OR. Pentostatin in chronic lymphocytic leukemia: a phase II trial of Cancer and Leukemia group B. J Clin Oncol 1989; 7: 433-438.
11. Saven A, Piro LD. 2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies. Ann Intern Med 1994; 120: 784-791.
12. O'Dwyer PJ, Wagner B, Leyland Jones B, Wittes RE, Cheson BD, Hoth DF. 2′-Deoxycoformycin (pentostatin) for lymphoid malignancies. Rational development of an active new drug. Ann Intern Med 1988; 108: 733-743.
13. Griffig J, Koob R, Blakley RL. Mechanisms of inhibition of DNA synthesis by 2-chlorodeoxyadenosine in human lymphoblastic cells. Cancer Res 1989; 49: 6923-6928.
14. Avery TL, Rehg JE, Lumm WC, Harwood FC, Santana VM, Blakley RL. Biochemical pharmacology of 2-chlorodeoxyadenosine in malignant human hematopoielic cell lines and therapeutic effects of 2-bromodeoxyadenosine in drug combinations in mice. Cancer Res 1989; 49:4972-4978.
15. Plunkett W, Huang P, Gandhi V. Metabolism and action of fludarabine phosphate. Semin Oncol 1990; 17: 3-17.
16. Parker WB, Shaddix SC, Chang C, White EL, Rose LM, Brockman RW, Shortnacy AT, Montgomery JA, Secrist JA, Bennett LL. Effects of 2-chloro-9-(2-deoxy-2-fluoro-β-D-arabinofuranosyl)adenine on K562 cellular metabolism and the inhibition of human ribonucleotide reductase and DNA polymerases by its 5′-triphosphate. Cancer Res 1991; 51: 2386-2394.
17. Hirota Y, Yoshioka A, Tanaka S, Watanabe K, Otani T, Minowada J, Matsuda A, Ueda T, Wataya Y. Imbalance of deoxyribonucleoside triphosphates, DNA double-strand breaks, and cell death caused by 2-chlorodeoxyadenosine in mouse FM3A cells. Cancer Res 1989; 49: 915-919.
18. Begleiter A, Verburg L, Israels LG, Johnston JB. Factors influencing the inhibition of repair of irradiation-induced DNA damage by 2′-deoxycoformycin and deoxyadenosine. Cancer Chemother Pharmacol 1992; 30: 65-69.
19. Seto S, Carrera CJ, Kubota M, Wasson DB, Carson DA. Mechanism of deoxyadenosine and 2-chlorodeoxyadenosine toxicity in nondividing human lymphocytes. J Clin Invest 1985; 75: 377-383.
20. Begleiter A, Glazer RI, Israels LG, Pugh L, Johnston JB. Induction of DNA strand breaks in chronic lymphocytic leukemia following treatment with 2′-deoxycoformycin in vivo and in vitro. Cancer Res 1987; 47: 2498-2503.
21. Begleiter A, Pugh L, Israels LG, Johnston JB. Enhanced cytotoxicity and inhibition of DNA damage repair in irradiated murine L5178Y lymphoblasts and human chronic lymphocytic leukemia cells treated with 2′-deoxycoformycin and deoxyadenosine in vitro. Cancer Res 1988; 48: 3981-3986.
22. Cohen A, Thompson E. DNA repair in nondividing human lymphocytes: inhibition by deoxyadenosine. Cancer Res 1986; 46: 1585-1588.
23. Huang P, Chubb S, Plunkett W. Termination of DNA synthesis by 9-beta-D-arabinofuranosyl-2-fluoroadenine. A mechanism for cytotoxicity. J Biol Chem 1990; 265: 16617-16625.
24. Hentosh P, Koob R, Blakley RL. Incorporation of 2-halogeno-2′-deoxyadenosine 5-triphosphates into DNA during replication by human polymerases alpha and beta. J Biol Chem 1990; 265: 4033-4040.
25. Yang S, Huang P, Plunkett W, Becker FF, Chan JYH. Dual mode of inhibition of purified DNA ligase I from human cells by 9-β-D-arabinofuranosyl-2-fluoroadenine triphosphate. J Biol Chem 1992; 267: 2345-2349.
26. Robertson LE, Chubb S, Meyn RE, Story M, Ford R, Hittelman WN, Plunkett W. Induction of apoptotic cell death in chronic lymphocytic leukemia by 2-chloro-2′-deoxyadenosine and 9-β-D-arabinosyl-2-fluoroadenine. Blood 1993; 81: 143-150.
27. Johnston JB, Lee K, Verburg L, Blondal J, Mowat MR, Israels LC, Begleiter A. Induction of apoptosis in CD4+ prolymphocytic leukemia by deoxyadenosine and 2′-deoxycoformycin. Leuk Res 1992; 16: 781-788.
28. Begleiter A, Peniuk H, Israels LC, Johnston JB. Inhibition of repair of bleomycin-induced DNA strand breaks by 2′-deoxycoformycin and its effect on antitumor activity in L5178Y lymphoblasts. Biochem Pharmacol 1992; 44: 2229-2233.
29. Johnston JB, Verburg L, Shore T, Williams M, Israels LG, Begleiter A. Combination therapy with nucleoside analogs and alkylating agents. Leukemia 1994; 8 (Suppl.): S140-S143.
30. Gora Tybor J, Robak T. Synergistic action of 2-chlorodeoxyadenosine and cyclophosphamide on murine leukemias L1210 and P388. Acta Haematol Pol 1993; 24: 177-182.
31. Kristensen J, Nygren P, Liliemark J, Fridborg H, Killander A, Simonsson B, Oeberg G, Larsson R. Interactions between cladribine (2-chlorodeoxyadenosine) and standard antileukemic drugs in primary cultures of human tumor cells from patients with acute myelocytic leukemia. Leukemia 1994; 8: 1712-1717.
32. Gregire V, Hunter N, Milas L, Brock WA, Plunkett W, Hittelman WN. Potentiation of radiation-induced regrowth delay in murine tumors by fludarabine. Cancer Res 1994; 54: 468-474.
33. Gandhi V, Robertson LE, Keating MJ, Plunkett W. Combination of fludarabine and arabinosylcytosine for treatment of chronic lymphocytic leukemia: clinical efficacy and modulation of arabinosylcytosine pharmacology. Cancer Chemother Pharmacol 1994; 34: 30-36.
34. Petzer AL, Bilgeri R, Zilian U, Haun M, Geisen FH, Pragnell I, Braunsteiner H, Konwalinka C. Inhibitory effect of 2-chlorodeoxyadenosine on granulocytic, erythroid, and T-lymphocytic colony growth. Blood 1991; 78: 2583-2587.
35. Begleiter A, Verburg L, Ashique A, Lee K, Israels LG, Mowat MRA, Johnston JB. Comparison of antitumor activities of 2-chlorodeoxyadenosine and 9-β-arabinosyl-2-fluoroadenine in chronic lymphocytic leukemia and marrow cells in vitro. Leukemia 1995; 9: 1875-1881.
36. O'Brien S, Kantarjian H, Estey E, Koller C, Robertson B, Beran M, Andreeff M, Pierce S, Keating M. Lack of effect of 2-chlorodeoxyadenosine therapy in patients with chronic lymphocytic leukemia refractory to fludarabine therapy. New Engl J Med 1994; 330: 319-322.
37. Liliemark J, Juliusson G. On the pharmacokinetics of 2-chloro-2′-deoxyadenosine in humans. Cancer Res 1991; 51: 5570-5572.
38. Adair CG, Bridges JM, Desair ZR. Can food affect the bioavailability of chlorambucil in patients with haematological malignancies? Cancer Chemother Pharmacol 1986; 17: 99-102.
39. Elias L, Stock-Novack D, Head DR, Grever MR, Weick JK, Chapman RA, Godwin JE, Metz EN, Appelbaum FR. A phase I trial of combination fludarabine monophosphate and chlorambucil in chronic lymphocytic leukemia: a Southwest Oncology Group study. Leukemia 1993; 7: 361-365.
40. Weiss M, Spiess T, Berman E, Kempin S. Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia. Leukemia 1994; 8: 1290-1293.
41. Tefferi A, Witzig TE, Reid JM, Li CY, Ames MM. Phase I study of combined 2-chlorodeoxyadenosine and chlorambucil in chronic lymphoid leukemia and low-grade lymphoma. J Clin Oncol 1994; 12: 569-574.
42. Zulian GB, Iten PA, Guetty-Alberto M, Antonioli V, Alberto P, Cerny T. Cladrabine (2-chlorodeoxyadenosine) with cyclophosphamide and prednisone as first-line treatment of low grade B-lymphoproliferative disorders. Proc Am Soc Clin Oncol 1995; 14: A1258.
43. Hochster H, Oken M, Bennet J, Wolf B, Gordon L, Raphael B, Gencarelli, Cassileth P. Efficacy of cyclophosphamide (CYC) and fludarabine (FAMP) as first line therapy of low-grade non-Hodgkin's lymphoma (NHL) - ECOG 1491. Blood 1994; 84 (Suppl. 1): 383a.
44. Rai KR, Peterson B, Kolitz J, Elias L, Shepard L, Hines J, Cheson B, Schiffer C. Fludarabine induces a high complete remission rate in previously untreated patients with active chronic lymphocytic leukemia (CLL). Blood 1995; 86 (Suppl. 1): 607a.
45. Hurta RA, Wright JA. Alterations in the activity and regulation of mammalian ribonucleotide reductase by chlorambucil, a DNA damaging agent. J Biol Chem 1992; 267: 7066-7071.